BREAST IMAGING FOR SCREENING AND DIAGNOSING CANCER

Policy Number: DIAGNOSTIC 105.19 T2
Effective Date: June 1, 2019

Table of Contents

<table>
<thead>
<tr>
<th>Conditions of Coverage</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions of Coverage</td>
<td>1</td>
</tr>
<tr>
<td>Coverage Rationale</td>
<td>2</td>
</tr>
<tr>
<td>Documentation Requirements</td>
<td>3</td>
</tr>
<tr>
<td>Definitions</td>
<td>3</td>
</tr>
<tr>
<td>Applicable Codes</td>
<td>4</td>
</tr>
<tr>
<td>Description of Services</td>
<td>5</td>
</tr>
<tr>
<td>Clinical Considerations</td>
<td>5</td>
</tr>
<tr>
<td>U.S. Food and Drug Administration</td>
<td>10</td>
</tr>
<tr>
<td>References</td>
<td>11</td>
</tr>
<tr>
<td>Policy History/Revision Information</td>
<td>13</td>
</tr>
<tr>
<td>Instructions for Use</td>
<td>13</td>
</tr>
</tbody>
</table>

Related Policies
- Omnibus Codes
- Preventive Care Services
- Radiology Procedures Requiring Precertification for eviCore Healthcare Arrangement

Applicable Lines of Business/Products
This policy applies to Oxford Commercial plan membership.

Benefit Type
General benefits package

Referral Required
Yes

Authorization Required
Yes1,2,3

Precertification with Medical Director Review Required
Yes1,2,3

Applicable Site(s) of Service
Office1,2,3, Outpatient1,2

Special Considerations
1Oxford has engaged eviCore healthcare to perform initial reviews of requests for precertification and medical necessity reviews for CPT/HCPCS codes 76376, 76377, 76391, 76499, 77046, 77047, 77048, 77049 and S8080 (Oxford continues to be responsible for decisions to limit or deny coverage and for appeals).
2Precertification is not required through eviCore healthcare or Oxford for CPT/HCPCS codes 76641, 76642, 77065, 77066, or 77067.
3Participating Providers in the Office Setting:
Precertification is required for services performed in the office of a participating provider. Non-Participating/Out-of-Network Providers in the Office Setting:
Precertification is not required, but is encouraged for out-of-network services performed in the office. If precertification is not obtained, Oxford will review for out-of-network benefits and medical necessity after the service is rendered.
Notes:

- All precertification requests for CPT/HCPCS codes 76376, 76377, 76391, 76499, 77046, 77047, 77048, 77049 and S8080 are handled by eviCore healthcare. To pre-certify one of these radiology procedures, call eviCore healthcare at 1-877-PRE-AUTH (1-877-773-2884) or log onto the eviCore healthcare web page using the Prior Authorization and Notification App. Refer to the Clinical Policy titled Radiology Procedures Requiring Precertification for eviCore healthcare Arrangement for additional requirements, if applicable.
- Oxford is responsible for all precertification and medical necessity reviews for CPT codes 0422T and 76498.

**COVERAGE RATIONALE**

**Important Note:** Oxford has engaged eviCore healthcare to perform initial reviews of requests for precertification and medical necessity reviews for CPT/HCPCS codes 0159T, 76377, 76499, 77046, 77047, 77048, 77049 and S8080. (Oxford continues to be responsible for decisions to limit or deny coverage and for appeals.)

To pre-certify a radiology procedure, call eviCore healthcare at 1-877-PRE-AUTH (1-877-773-2884) or log onto the eviCore healthcare web page using the Prior Authorization and Notification App.

eviCore has established an infrastructure to support the review, development, and implementation of comprehensive outpatient imaging criteria. The radiology evidence-based guidelines and management criteria are available on the eviCore healthcare website using the Prior Authorization and Notification App.

Refer to the Clinical Policy titled Radiology Procedures Requiring Precertification for eviCore healthcare Arrangement for applicable CPT/HCPCS codes and additional requirements, if applicable.

**Note:** This policy does not address preventive breast cancer screening; refer to the Clinical Policy titled Preventive Care Services for more information.

The following are proven and medically necessary:

- Digital mammography for individuals with dense breast tissue
- Breast Magnetic Resonance Imaging (MRI) for individuals who are high risk for breast cancer as defined as having any of the following:
  - Personal history of breast cancer
  - Two or more first degree relatives with breast cancer
  - History of radiation therapy to the chest
  - Dense breast tissue with any one of the following risk factors
    - Lifetime risk of breast cancer of 20% or greater, using standard risk assessment models that are defined by family history
    - Personal history of BRCA1 or BRCA2 gene mutations
    - History of radiation therapy to the chest between the ages of 10-30
    - First-degree relative of a BRCA1 or BRCA2 mutation carrier who has not yet been tested
    - Personal history or has first degree relative who has Li Fraumeni Syndrome, Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome
- Diagnostic breast ultrasound

The following are unproven and not medically necessary due to insufficient evidence of efficacy:

- Automated Breast Ultrasound system
- Breast MRI for individuals with dense breast tissue not accompanied by defined risk factors as described above
- Computer-Aided Detection (CAD)
- Computer-Aided Tactile Breast Imaging
- Electrical Impedance Scanning (EIS)
- Magnetic Resonance Elastography (MRE)
- Scintimammography

**Note:** For additional indications for breast MRI, refer to the Clinical Guideline titled Cardiology and Radiology Imaging Guidelines – Breast Imaging Guidelines.
DOCUMENTATION REQUIREMENTS

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The documentation requirements outlined below are used to assess whether the member meets the clinical criteria for coverage but do not guarantee coverage of the service requested.

Required Clinical Information

Breast Imaging for Screening and Diagnosing Cancer

- Provider should call the number on the member’s ID card when referring for radiology services
- Medical notes documenting all of the following:
  - Recent history and physical
  - Documentation to support medical necessity (i.e., family history, prior treatment, genetic testing results, other imaging studies and diagnostic results, etc.)
  - Applicable CPT code

DEFINITIONS

Automated Breast Ultrasound: Automated Breast Ultrasound is the first and only ultrasound system developed and US Food and Drug Administration (FDA) approved specifically for breast cancer screening in women with dense breast tissue who have not had previous breast biopsies or surgeries. It is used as an adjunct to mammography. The high center-frequency significantly sharpens detail resolution while the ultra-broadband performance simultaneously delivers distinct contrast differentiation. (ACS, 2016)

Breast Specific Gamma Imaging (BSGI): BSGI, also known as scintimammography (SMM) or molecular breast imaging (MBI) is a noninvasive diagnostic technology that detects tissues within the breast that accumulate higher levels of a radioactive tracer that emit gamma radiation. The test is performed with a gamma camera after intravenous administration of radioactive tracers. Scintimammography has been proposed primarily as an adjunct to mammography and physical examination to improve selection for biopsy in patients who have palpable masses or suspicious mammograms. (ACS, 2016)

Breast Ultrasound: Ultrasound, also known as sonography, is an imaging method using sound waves rather than ionizing radiation to a part of the body. For this test, a small, microphone-like instrument called a transducer is placed on the skin (which is often first lubricated with ultrasound gel). It emits sound waves and picks up the echoes as they bounce off body tissues. The echoes are converted by a computer into a black and white image on a computer screen. Ultrasound is useful for evaluating some breast masses and is the only way to tell if a suspicious area is a cyst (fluid-filled sac) without placing a needle into it to aspirate (draw out) fluid. Cysts cannot accurately be diagnosed by physical exam alone. Breast Ultrasound may also be used to help doctors guide a biopsy needle into some breast lesions. (ACS, 2016)

Computer-Aided Detection (CAD) with MRI of the Breast: Computer-Aided Detection has been used to aid radiologists’ interpretation of contrast-enhanced MRI of the breast, which is sometimes used as an alternative to mammography or other screening and diagnostic tests because of its high sensitivity in detecting breast lesions, even among those in whom mammography is less accurate (e.g., younger women and those with denser breasts). (ACS, 2016)

Computer-Aided Detection (CAD) for Ultrasound: CAD systems for ultrasound use pattern recognition methods to help radiologists analyze images and automate the reporting process. These systems have been developed to promote standardized Breast Ultrasound reporting. (ACS, 2016)

Computer-Aided Tactile Breast Imaging: Tactile breast imaging includes placing a tactile array sensor in contact with the breast. As the clinician gently moves the hand-held sensor across the breast and underarm area, data signals are then processed into multi-dimensional color images that instantly appear on a computer screen in real-time, allowing the clinician to view the size, shape, hardness and location of suspicious masses immediately. (ACS, 2016)

Electrical Impedance Scanning (EIS): EIS was developed as a confirmatory test to be used in conjunction with mammography. The device detects abnormal breast tissue using small electrical currents. Since malignant tissue tends to conduct more electricity than normal tissue, the electrical current produced creates a conductivity map of the breast which automatically identifies sites that appear suspicious. The transmission of electricity into the body is via an electrical patch on the arm or a handheld device which travels to the breast. This is measured by a probe on the surface of the skin. (ACS, 2016)
**Magnetic Resonance Imaging (MRI):** MRI is a non-invasive imaging modality that uses magnetic and radiofrequency fields to image body tissue producing very detailed, cross-sectional pictures of the body. Inconsistent with CT, MRI uses no ionizing radiation and is generally a safe procedure. MRI is sometimes used in combination with mammography. (National Institute of Biomedical Imaging, 2017)

**Magnetic Resonance Elastography (MRE) of the Breast:** MRE of the breast is a phase-contrast-based MRI technique that is based upon quantitative differences in the mechanical properties of normal and malignant tissues. Specifically, the elastic modulus of breast cancer tissue is approximately 5- to 20-fold higher than that of the surrounding fibroglandular tissue, i.e., breast cancers are usually harder than normal tissues. This difference can be measured by applying a known stressor and measuring the resulting deformation. MRE is performed by a radiologist in an MRI suite equipped with the electromechanical driver and integrated radiofrequency coil unit. (ACS, 2016)

### APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies may apply.

**Coding Clarification:** Computer-aided detection (CAD) is included with the MRI breast CPT code 77048 and 77049 procedures. If CAD is performed with these codes, there is no additional reimbursement.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0422T</td>
<td>Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral)</td>
</tr>
<tr>
<td>76376</td>
<td>3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; not requiring image postprocessing on an independent workstation</td>
</tr>
<tr>
<td>76377</td>
<td>3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation</td>
</tr>
<tr>
<td>76391</td>
<td>Magnetic resonance (e.g., vibration) elastography</td>
</tr>
<tr>
<td>76498</td>
<td>Unlisted magnetic resonance procedure (e.g., diagnostic, interventional)</td>
</tr>
<tr>
<td>76499</td>
<td>Unlisted diagnostic radiographic procedure</td>
</tr>
<tr>
<td>76641</td>
<td>Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; complete</td>
</tr>
<tr>
<td>76642</td>
<td>Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited</td>
</tr>
<tr>
<td>77046</td>
<td>Magnetic resonance imaging, breast, without contrast material; unilateral</td>
</tr>
<tr>
<td>77047</td>
<td>Magnetic resonance imaging, breast, without contrast material; bilateral</td>
</tr>
<tr>
<td>77048</td>
<td>Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral</td>
</tr>
<tr>
<td>77049</td>
<td>Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral</td>
</tr>
<tr>
<td>77065</td>
<td>Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral</td>
</tr>
<tr>
<td>77066</td>
<td>Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral</td>
</tr>
<tr>
<td>77067</td>
<td>Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed</td>
</tr>
</tbody>
</table>

*CPT® is a registered trademark of the American Medical Association*
DESCRIPTION OF SERVICES

Mammography remains the generally accepted standard for breast cancer screening and diagnosis. However, efforts to provide new insights regarding the origins of breast disease and to find different approaches for addressing several key challenges in breast cancer, including detecting disease in mammographically dense tissue, distinguishing between malignant and benign lesions, and understanding the impact of neoadjuvant chemotherapies, has led to the investigation of several novel methods of breast imaging for breast cancer management.

This policy will focus on automated breast ultrasound, breast specific gamma imaging, ultrasound for breast cancer screening and diagnosing of breast cancer, use of CAD with MRI as well as breast ultrasound. Additional approaches include computer-aided tactile imaging, electrical impedance scanning, MRI and MRE.

BENEFIT CONSIDERATIONS

Oxford Commercial Members who have Out-Of-Network Benefits

Oxford commercial members who have out-of-network benefits and who are part of New York Large and Small groups, Connecticut Large and Small groups and New Jersey Large groups, also need to obtain precertification for MRI, MRA, PET, CT and Nuclear Medicine studies when seeing an out-of-network provider.

Connecticut (CT) Products

For members enrolled on CT products, an insurer shall provide additional benefits for comprehensive ultrasound screening of an entire breast or breasts if a mammogram demonstrates heterogeneous or dense breast tissue based on the Breast Imaging Reporting and Data System established by the American College of Radiology or if a woman is believed to be at increased risk for breast cancer due to family history or prior personal history of breast cancer, positive genetic testing or other indications as determined by a woman’s physician or advanced practice registered nurse.

New Jersey (NJ) Small, NJ School Board and NJ Municipality Products

For members enrolled on NJ Small, NJ School Board and NJ Municipality products, services indicated as requiring a precertification require medical necessity review. This review may be requested prior to service. If a medical necessity review is not requested by the provider prior to service, the medical necessity review will be conducted after the service is rendered with no penalty imposed for failure to request the review prior to rendering the service. It is the referring physician’s responsibility to provide medical documentation to demonstrate clinical necessity for the study that is being requested (for review prior to service) or has been rendered (for review after service was provided).

For additional information on baseline mammogram services, refer to the Clinical Policy titled Preventive Care Services.

CLINICAL EVIDENCE

Automated Breast Ultrasound System (ABUS)

An archived 2013 Hayes report evaluating automated breast ultrasound system (ABUS), found that the results presented in the majority of the study abstracts report overall favorable results when using three-dimensional automated breast ultrasound. Further review is required to confirm abstract content and, therefore, conclusions about the safety and effectiveness of this technology cannot be made until a full assessment has been completed.

Hellgren et al. (2017) conducted a study to compare the sensitivity and specificity of Automated Breast Volume Scanners (ABVS) to handheld breast US for detection of breast cancer in the situation of recall after mammography screening. A total of 113 women, five with bilateral suspicious findings, undergoing handheld breast US due to a suspicious mammographic finding in screening, underwent additional ABVS. The methods were assessed for each breast and each detected lesion separately and classified into two categories: breasts with mammographic suspicion of malignancy and breasts with a negative mammogram. Results Twenty-six cancers were found in 25 women. In the category of breasts with a suspicious mammographic finding, the sensitivity of both handheld US and ABVS was 88% (22/25). The specificity of handheld US was 93.5% (87/93) and ABVS was 89.2% (83/93). In the category of breasts with a negative mammography, the sensitivity of handheld US and ABVS was 100% (1/1). The specificity of handheld US was 100% (102/102) and ABVS was 94.1% (96/102). The authors concluded that ABVS can potentially replace handheld US in the investigation of women recalled from mammography screening due to a suspicious finding. Due to the small size of this study population, further investigation with larger study populations is necessary before the implementation of such practice.

Breast Imaging for Screening and Diagnosing Cancer
UnitedHealthcare Oxford Clinical Policy
©1996-2019, Oxford Health Plans, LLC
Effective 06/01/2019
Kim et al (2016) conducted a prospective study to compare the diagnostic performance of handheld ultrasound (US) and an automated breast volume scanner (ABVS) as second-look US techniques subsequent to preoperative breast magnetic resonance imaging (MRI). From March to September 2014, both types of second-look US examinations were performed on 40 patients with breast cancer who had 76 additional suspicious lesions detected via preoperative breast MRI. Each second-look US modality was reviewed independently and the detection rate of each, the correlation between the detection rate, and the MRI factors (size, distance, and enhancement type) were evaluated. The detection rate of the ABVS was higher than that of handheld US for the second-look examination (94.7% versus 86.8%). Among the 76 total lesions, 7 were only identified by the ABVS, 1 was only found by handheld US, and 3 were not detected by either the ABVS or handheld US. When we analyzed the correlation between the detection rate and MRI factors, the only meaningful factor was the enhancement type. The ability to detect a non-mass lesion was lower than the ability to detect a mass-type lesion for both the ABVS and handheld US. It was concluded that for a second-look US examination subsequent to preoperative breast MRI in patients with breast cancer, the ABVS is a more efficient modality than handheld US for preoperative evaluations. However, both techniques have limitations in detecting non mass lesions. This study is limited to a small sample size.

Prosch et al. (2011) conducted a prospective diagnostic study. The study examined 148 breasts of 76 patients with handheld ultrasound (US) and ABUS. The ABUS data were evaluated separately by two investigators. The inter-observer agreement for the breast imaging reporting and data system (BI-RADS) classification among the two observers using ABUS was high, the agreement with handheld US was moderate. The sensitivity in the detection of breast cancer was 87.5% for handheld US and 75% for the ABUS evaluation by observer 1. The sensitivity was 87.5% for the ABUS evaluation and 83% for mammography by observer 2. The authors concluded that ABUS examinations focusing on the BI-RADS classification have low inter-observer variability, compared to handheld US.

**Magnetic Resonance Imaging for High Risk Individuals including Dense Breasts**

In studies comparing the effectiveness of breast MRI to mammography for screening of high-risk individuals for breast cancer, MRI increased the cancer detection rate.

Literature review located three systematic reviews that included women at high risk of developing breast cancer. Warner et al (2008) review included 11 studies published through 2008. Two reviews by Phi et al (2015, 2017) reported 2 individual patient data meta-analyses from the same 6 studies published between 2010 and 2013. Phi et al (2015) included the women with BRCA1 or BRCA2 variants and Phi et al (2017) included the women with a strong family history of breast without a known variant. The authors of these studies concluded that screening breast MRI is more sensitive but less specific than mammography for the detection of invasive cancers in high-risk women. The sensitivity of combined MRI and mammography was approximately 93% or higher in the reviews while the sensitivity of mammography alone was between approximately 40% and 55%. The Warner (2008) review did not present a risk of bias or quality assessment of included studies. Phi (2015) assessed quality using the QUADAS-2 tool. All included studies were considered good quality.

**Professional Societies/Guidelines**

**American Cancer Society (ACS)**

The available data for MRI imaging is inconclusive for its use for routine screening in women who are not at high risk. The American Cancer Society (ACS, 2017) guidelines specifically recommend against annual MRI screening in women at less than a 15% lifetime risk of breast cancer.

**National Comprehensive Cancer Network® (NCCN)**

The 2018 National Comprehensive Cancer Network® (NCCN) guidelines recommend annual MRI in addition to mammogram for those individuals with an increased risk of breast cancer, defined as those with a history suggestive of or known genetic predisposition for breast cancer, starting at age 25 and individuals who have received thoracic radiation therapy between 10 and 30 years of age.

**American College of Obstetricians and Gynecologists (ACOG, 2019)**

The American College of Obstetricians and Gynecologists recommends routine screening with use of digital mammography for women diagnosed with dense breasts. They do not recommend routine use of alternative or adjunctive tests to screening mammography in women with dense breasts who are asymptomatic and have no additional risk factors. The College strongly supports additional research to identify more effective screening methods that will enhance meaningful improvements in cancer outcomes for women with dense breasts and minimize false-positive screening results. ACOG also recommends that health care providers comply with state laws that may require disclosure to women of their breast density as recorded in a mammogram report.
Breast Imaging for Screening and Diagnosing Cancer

American College of Radiology Appropriateness Criteria for Breast Cancer Screening
The American College of Radiology Appropriateness Criteria for Breast Cancer Screening (2017) considers MRI for screening high-risk women including women with a BRCA gene mutation and their untested first-degree relatives, women with a history of chest irradiation between 10 to 30 years of age, and women with 20% or greater lifetime risk of breast cancer usually appropriate.

American Society of Breast Surgeons
A 2017 consensus guideline by the American Society of Breast Surgeons on diagnostic and screening magnetic resonance imaging of the breast also supports the use of MRI as a screening technique in women. The guideline particularly supports women age 25 or older with a BRCA gene mutation, women with other germline mutations known to predispose to a high risk of breast cancer, women with a history of chest irradiation, and women with a 20%-25% or greater estimated lifetime risk of breast cancer based on models primarily based on family history.

Magnetic Resonance Elastography of the Breast
A prospective study by Siegmann et al. (2010) evaluated the value of adding magnetic resonance elastography (MRE) to contrast-enhanced MR imaging (MRI) for evaluating breast lesions in 57 patients. The sensitivity of MRI was 97.3% whereas specificity was 55%. If contrast-enhanced MRI was combined with α0 (indicator of tissue stiffness), the diagnostic accuracy could be significantly increased. The authors concluded that combining MRE with MRI increase the diagnostic performance of breast MRI; however, larger studies are needed to validate the results and to identify the patients best suited for a combined procedure.

Breast Specific Gamma Imaging (BSGI) (also known as Scintimammography)
Guo et al (2016). In a 2016 systematic review and meta-analysis, the authors sought to establish if Tc-99m sestamibi scintimammography is useful in the prediction of neoadjuvant chemotherapy responses in breast cancer. Electronic database were searched for relevant publications in English, and fourteen studies, for a total of 503 individuals, fulfilled the inclusion criteria. The results indicated that Tc-99m MIBI scintimammography had acceptable sensitivity in the prediction of neoadjuvant chemotherapy response in breast cancer; however, its relatively low specificity showed that a combination of other imaging modalities would still be needed. Subgroup analysis indicated that performing early mid-treatment Tc-99m MIBI scintimammography (using the reduction rate of one or two cycles or within the first half-courses of chemotherapy compared with the baseline) was better than carrying out later (after three or more courses) or post-treatment scintimammography in the prediction of neoadjuvant chemotherapy response.

Brem at al (2016). The authors conducted this retrospective review to determine the incremental increase in breast cancer detection when BSGI is used as an adjunct to mammography in women at increased risk for breast cancer. 849 patients undergoing BSGI from April 2010 through January 2014 were retrospectively reviewed. Eligible patients were identified as women at increased risk for breast cancer and whose most recent mammogram was benign. Examinations exhibiting focally increased radiotracer uptake were considered positive. Incremental increase in cancer detection was calculated as the percentage of mammographically occult BSGI-detected breast cancer and the number of mammographically occult breast cancers detected per 1,000 women screened. Reviewed for this study were patients in whom 14 BSGI examinations detected mammographically occult breast cancer. Patients ranged in age from 26 to 83 with a mean age of 57 Eleven of 14 cancers were detected in women with dense breasts. The addition of BSGI to the annual breast screen of asymptomatic women at increased risk for breast cancer yields 16.5 cancers per 1,000 women screened. When high-risk lesions and cancers were combined, BSGI detected 33.0 high-risk lesions and cancers per 1,000 women screened. The authors concluded that BSGI is a reliable adjunct modality to screening mammography that increases breast cancer detection by 1.7% (14/849) in women at increased risk for breast cancer, comparable to results reported for breast MRI. BSGI is beneficial in breast cancer detection in women at increased risk, particularly in those with dense breasts. Limitation of this study is retrospective study design.

In the 2013 ECRI Evidence Report, Noninvasive Diagnostic Tests for Breast Abnormalities found that only women with a pre-scintimammography suspicion of malignancy of 5 percent or less will have their post-scintimammography suspicion of malignancy change sufficiently to suggest that a change in patient management may be appropriate.

An Archived 2015 Hayes report evaluating breast-specific gamma imaging (BSGI) found that the available evidence does not provide conclusive evidence that breast-specific gamma imaging can be relied on rather than biopsy, US, or MRI in women who have suspicious breast lesions on mammograms. In several of the reviewed studies, BSGI detected some cancerous lesions that were not detected by mammography; however, these studies did not report whether the increased detection corresponded to a statistically significant increase in the sensitivity of BSGI compared with mammography. In the studies that provided data on patient management, BSGI was not rigorously compared with MRI or US to determine whether it was more effective. Only two studies reported the statistical significance of results, both of which indicated that BSGI was more specific than MRI. Although further studies may indicate that breast-specific gamma imaging has greater sensitivity than ultrasonography and MRI, breast-specific gamma imaging has the disadvantage that it exposes the patient to radiation. In addition, unlike biopsy, breast-specific gamma imaging does not provide a definitive diagnosis since it incorrectly indicates that 15% to 40% of benign lesions are...
cancerous. The quality of the evidence is low due to the predominately retrospective study design, small sample sizes, and, in some cases, lack of statistical analysis of results. Additional studies are needed to determine the place in therapy of BSGI versus the alternatives.

Kim (2012) evaluated the adjunctive benefits of BSGI versus MRI in breast cancer patients with dense breasts. This study included a total of 66 patients with dense breasts (breast density greater than 50%) and already biopsy-confirmed breast cancer. All of the patients underwent BSGI and MRI as part of an adjunct modality before the initial therapy. Of 66 patients, the 97 undetermined breast lesions were newly detected and correlated with the biopsy results. Twenty-six of the 97 breast lesions proved to be malignant tumors; the remaining 71 lesions were diagnosed as benign tumors. The sensitivity and specificity of BSGI were 88.8% and 90.1% respectively, while the sensitivity and specificity of MRI were 92.3% and 39.4%, respectively. MRI detected 43 false-positive breast lesions, 37 (86.0%) of which were correctly diagnosed as benign lesions using BSGI. In 12 malignant lesions less than 1 cm, the sensitivities of BSGI and MR imaging were 83.3% and 91.7% respectively. The author concluded that BSGI showed an equivocal sensitivity and a high specificity compared to MRI in the diagnosis of breast lesions. In addition, BSGI had a good sensitivity in discriminating breast cancers less than or equal to 1 cm. The results of this study suggested that BSGI could play a crucial role as an adjunctive imaging modality which can be used to evaluate breast cancer patients with dense breasts. The study was limited by small sample size; larger prospective studies are needed to determine the true sensitivity and specificity of BSGI.

Based on 44 studies of scintimammography, an analysis found that for non-palpable lesions, the specificity of scintimammography was 39.2% (at a fixed 95% sensitivity). At the mean threshold of the included studies, the sensitivity was 68.7% and specificity was 84.8%. The analysis also found that in women with non-palpable lesions, the negative likelihood ratio of scintimammography was 0.41 (i.e., if a woman with a non-palpable lesion is diagnosed as having no cancer by scintimammography, her chance of having breast cancer drops from 20% to 9.3%). (AHRQ, 2006, updated 2012)

A meta-analysis of scintimammography included 5,473 patients from studies performed since 1997. The overall sensitivity was 85% and the specificity was 84% for single-site trial studies, and for multi-center trial studies the overall sensitivity was 85% and the specificity was 83%. (Hussain and Buscombe, 2006) Another meta-analysis evaluating scintimammography included 5,340 patients from studies published between January 1967 and December 1999. The aggregated summary estimates of sensitivity and specificity for scintimammography were 85.2% and 86.6% respectively. The authors concluded that scintimammography may be used effectively as an adjunct to mammography when additional information is required to reach a definitive diagnosis. The authors also indicated that the role of scintimammography should be assessed on the basis of large, multi-center studies. (Liberman et al., 2003)

Professional Societies/Organizations
t
American Cancer Society (ACS)
According to the 2016 ACS guidelines, routine breast cancer screening with scintimammography is not recommended.

American College of Radiology (ACR)
According to the 2017 appropriateness criteria for breast cancer screening, there is insufficient evidence to support the use of breast specific gamma imaging (BSGI).

Blue Cross Blue Shield TEC Assessment
A 2013 TEC Assessment by the Blue Cross Blue Shield Association evaluated the use of BSGI, or scintimammography with breast-specific gamma camera as a diagnostic modality for screening to detect breast tumors and concluded that there is no evidence of improved health outcomes.

Society of Nuclear Medicine and Molecular Imaging (SNMM) (formerly Society of Nuclear Medicine)
SNM published updated 2012 procedure standards for breast scintigraphy with breast-specific gamma cameras that indicate that further study is needed to determine the population and usefulness most likely to benefit from this procedure. This guideline lists potential indications and cites references for each indication but does not provide a systemic review of the literature, including assessment of study quality. The guideline is based on consensus, and most of it is devoted to procedures and specifications of the examination, documentation and recording, quality control and radiation safety.

Electrical Impedance Scanning (EIS)
An archived 2011 Hayes technology brief evaluating electrical impedance scanning (EIS), found that EIS can detect malignant breast tissue in some patients; however, the sensitivity, specificity, and negative predictive value (NPV) of this technique do not appear sufficient to rely on it as a substitute in patients who have suspicious lesions. Further studies of EIS are needed to assess its effectiveness as an adjunct to mammography, in women who meet all criteria specified by the FDA for use of EIS.
In a prospective, multi-center study, Wang et al (2010) reported the sensitivity and specificity for the combination of EIS and ultrasound in identifying breast cancer and calculated the relative risk of breast cancer in young women. The young women (583 cases) scheduled for mammary biopsy underwent EIS and ultrasound, respectively. EIS and ultrasound results were compared with final histopathology results. Of the 583 cases, 143 were diagnosed with breast cancer. The relative probability of breast cancer for the young women was detected by EIS, ultrasound, and the combination method. The authors concluded that the combination of EIS and ultrasound is likely to become an applicable method for early detection of breast cancer in young women.

A prospective, multicenter clinical trial by Stojadinovic et al. (2005) evaluated EIS in 1,103 women. Twenty-nine cancers with a mean tumor size 1.7 cm were confirmed thru biopsy. Electrical impedance scanning had 17% sensitivity, 90% specificity, and a negative predictive value (NPV) of 98%. Statistically significant increases in specificity were observed for women who were premenopausal and women who were not using hormone replacement therapy. False-positive rates were increased in postmenopausal women and those taking exogenous hormones. While the authors concluded that EIS appears promising for early detection of breast cancer, the increased false positive rates in postmenopausal women and those taking exogenous hormones is concerning.

**Professional Societies/Organizations**

**American Cancer Society (ACS)**

In a 2016 update on experimental breast imaging, the ACS states that while this test is approved by the Food and Drug Administration (FDA) to help classify tumors found on mammograms, at this time there hasn’t been enough clinical testing to use it in breast cancer screening.

**National Comprehensive Cancer Network (NCCN)**

The 2018 NCCN Clinical Practice Guideline for Breast Cancer Screening and Diagnosis does not mention EIS as a diagnostic tool in the diagnosis or management of breast tumors.

**Society of Breast Imaging (SBI)**

In the 2013 SBI Position Statement entitled ‘Use of Alternative Imaging Approaches to Detection of Breast Cancer’ states that the following: “Often predicated on the increased vascularity associated with cancer, techniques to detect increased heat production, oxygen consumption, electrical impedance, light absorption, microwave transmission, and nitrous oxide production have indicated changes in the breast containing cancer that may assist in detection or diagnosis. While many of these approaches have received FDA approval for safety, such techniques remain either experimental or investigational, given the lack of standard techniques that can be uniformly applied and paucity of sufficient research to substantiate reliability of results. None of these tests have been shown to reduce mortality among tested women in randomized controlled trials.” Mammography provides the only examination satisfying both the benchmarks for screening and diagnosis based on objective and randomized clinical trials.

**Computer-Aided Detection with MRI of the Breast**

**Professional Societies/Technology Assessments**

**American College of Radiology (ACR) Practice Guideline for Performing and Interpreting Magnetic Resonance Imaging (MRI)**

In 2017 the American College of Radiology (ACR) revised the practice parameter for performing and interpreting Magnetic Resonance Imaging. The use of computer aided detection (CAD)/computer aided evaluation (CAE) with breast MRI is not specifically recommended or addressed.

**Blue Cross Blue Shield Association (BCBSA) Technology Evaluation Center (TEC)**

The Blue Cross Blue Shield Association (BCBSA) Technology Evaluation Center (TEC) completed a technology assessment in 2006 for CAD with MRI and concluded that there is insufficient evidence to assess whether the use of CAD systems would maintain or increase the sensitivity, specificity, and recall rates of MRI of the breast. Given the inability to evaluate these intermediate outcomes, it is not possible to assess the impact of CAD on health outcomes such as treatment success among breast cancer patients or survival. (BCBSA, 2006c)

**National Comprehensive Cancer Network (NCCN)**

Breast Cancer Screening and Diagnosis (2018) does not address the use of computer aided detection (CAD)/computer aided evaluation (CAE) for breast MRI testing.

**Computer-Aided Detection for Ultrasound**

Cho et al (2016) conducted a retrospective study to compare the detection of breast cancer using full-field digital mammography (FFDM), FFDM with computer-aided detection (FFDM+CAD), ultrasound (US), and FFDM+CAD plus US (FFDM+CAD+US), and to investigate the factors affecting cancer detection. This study was conducted from 2008 to

Breast Imaging for Screening and Diagnosing Cancer
UnitedHealthcare Oxford Clinical Policy

©1996-2019, Oxford Health Plans, LLC

Effective 06/01/2019
2012, and 48,251 women underwent FFDM and US for cancer screening. The clinical and pathological data was reviewed to investigate factors affecting cancer detection, and used generalized estimation equations to compare the cancer detectability of different imaging modalities. The results of this study showed the detectability of breast cancer by US or FFDM+CAD+US to be superior to that of FFDM or FFDM+CAD. However, cancer detectability was not significantly different between FFDM versus FFDM+CAD and US alone versus FFDM+CAD+US. The tumor size influenced cancer detectability by all imaging modalities. In FFDM and FFDM+CAD, the non-detecting group consisted of younger patients and patients with a denser breast composition. In breast US, carcinoma in situ was more frequent in the non-detecting group. The authors concluded that for breast cancer screening, breast US alone is satisfactory for all age groups, although FFDM+CAD+US is the perfect screening method. Patient age, breast composition, and pathological tumor size and type may influence cancer detection during screening. The study is also limited by small sample size, retrospective and non-blinded study design.

**Professional Societies**

**American College of Radiology (ACR)**

The ACR Practice Guideline for the performance of screening and diagnostic mammography (2014) states "Double reading and computer-aided detection (CAD) may slightly increase the sensitivity of mammographic interpretation, and may be used. However, this sensitivity is at the expense of decreased specificity with increased recall and biopsy rates.

**Computer-Aided Tactile Breast Imaging**

Tasoulis et al. (2014) unnecessary referrals of patients with breast lumps represent a significant issue, since only a few patients actually have lumps when examined by a breast specialist. Tactile imaging (TI) is a novel modality in breast diagnostics armamentarium. The aim of this study was to assess TI's diagnostic performance and compare it to clinical breast examination (CBE). This is a prospective, blinded, comparative study of 276 consecutive patients. All patients underwent conventional imaging and tissue sampling if either a radiological or a palpable abnormality was present. Sensitivity, specificity and positive and negative predictive values for CBE and TI were calculated. Radiological findings and final diagnosis based on histology and/or cytology were used as reference standards. Receiver operator characteristic (ROC) curve analysis was also performed for each method. Sensitivity and specificity of TI in detecting radiologically proven abnormalities were 85.5% and 35%, respectively. CBE's sensitivity was 80.3% and specificity 76%. In detecting a histopathological entity according to histology/cytology, sensitivity was 88.2% for TI and 81.6% for CBE. Specificity was 38.5% and 85.7% for TI and CBE, respectively. These results suggest a trend towards higher sensitivity of TI compared to CBE but significantly lower specificity. Subgroup analysis revealed superior sensitivity of TI in detecting a histological entity in pre-menopausal women. However, CBE's overall performance was superior compared to TI's according to ROC curve analysis. Although further research is necessary, the use of TI by the primary care physician as a selection tool for referring patients to a breast specialist should be considered especially in pre-menopausal women.

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Mammographic x-ray systems are classified as Class II devices. The FDA regulates the marketing of mammography devices and regulates the use of such devices via the Mammography Quality Standards Act (MQSA). The FDA has granted pre-market approval to several digital mammography systems (product code MUE) for breast cancer screening and diagnosis.

**Magnetic Resonance Elastography of the Breast**

See the following website for more information on devices used for elastography of the breast. Search by product name LNH in device name section: [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm).

**Breast Specific Gamma Imaging (BSGI)**

BSGI for diagnosing breast cancer is a procedure and, therefore, is not subject to FDA regulation. However, the equipment used to conduct BSGI is subject to FDA regulation. The cameras used during BSGI are considered Class I radiologic devices. A scintillation (gamma) camera is a device intended to image the distribution of radionuclides in the body by means of a photon radiation detector. [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm).

**Automated Breast Ultrasound System (ABUS)**

Automated breast (or whole breast) ultrasound devices are regulated by the FDA as Class III devices. See the following website for more information on devices used for Automated Breast Ultrasound Systems. Search by product name in device name section: [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm).
Electrical Impedance Scanning

These devices are approved as an adjunct to mammography in patients whose lesions are American College of Radiology (ACR) Breast Imaging-Reporting and Data System (BI-RADS) category III (probably benign) or IV (suspicious abnormality), based on mammography. See the following website for more information on devices used for Electrical Impedance Scanning. Search by product name in device name section:

Computer Aided Detection for MRI of the Breast

See the following website for more information on devices used for Computer-Aided Detection for MRI of the Breast. Search by product name in device name section: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm.

Computer-Aided Detection for Ultrasound

See the following website for more information on devices used for Computer-Aided Detection for Ultrasound. Search by product names MYN and LLZ in device name section:

REFERENCES

The foregoing Oxford policy has been adapted from an existing UnitedHealthcare national policy that was researched, developed and approved by UnitedHealthcare Medical Technology Assessment Committee. [2019T0375Y]


Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Breast-specific gamma imaging (BSGI), molecular breast imaging (MBI), or scintimammography with breast-specific gamma camera. TEC Assessments 2013; Volume 28.


CT Insurance Code: §38a-530.


### POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/2019</td>
<td><strong>Template Update</strong>&lt;br&gt;• Added <em>Documentation Requirements</em> section</td>
</tr>
<tr>
<td></td>
<td>• Updated conditions of coverage/precertification requirements; added language to indicate precertification requests for CPT/HCPCS codes 0422T, 76376, 76377, 76391, 76498, 76499, 77046, 77047, 77048, 77049 and S8080 require Medical Director review&lt;br&gt;• Updated coverage rationale:&lt;br&gt;  o Simplified content&lt;br&gt;  o Replaced references to “patients” with “individuals”&lt;br&gt;  o Modified language to clarify:&lt;br&gt;    ▪ This policy does not address preventive breast cancer screening; refer to the Clinical Policy titled <em>Preventive Care Services</em> for more information&lt;br&gt;    ▪ <em>Diagnostic</em> breast ultrasound is proven and medically necessary&lt;br&gt;  o Added reference link to the <em>Cardiology and Radiology Imaging Guidelines – Breast Imaging Guidelines</em> for information on additional indications for breast MRI</td>
</tr>
<tr>
<td>06/01/2019</td>
<td>• Updated definitions:&lt;br&gt;  o Added definition of (relocated from the <em>Description of Services</em> section):&lt;br&gt;    ▪ Automated Breast Ultrasound&lt;br&gt;    ▪ Breast Specific Gamma Imaging (BSGI)&lt;br&gt;    ▪ Breast Ultrasound&lt;br&gt;    ▪ Computer-Aided Detection (CAD) for Ultrasound&lt;br&gt;    ▪ Computer-Aided Tactile Breast Imaging&lt;br&gt;    ▪ Electrical Impedance Scanning (EIS)&lt;br&gt;    ▪ Magnetic Resonance Imaging (MRI)&lt;br&gt;    ▪ Magnetic Resonance Elastography (MRE) of the Breast&lt;br&gt;  o Modified definition of “Computer-Aided Detection (CAD) with MRI of the Breast” (relocated from the <em>Description of Services</em> section)&lt;br&gt;• Revised benefit considerations; added language for <em>Connecticut (CT) Products</em> to indicate an insurer shall provide additional benefits for comprehensive ultrasound screening of an entire breast or breasts if a mammogram demonstrates heterogeneous or dense breast tissue based on the <em>Breast Imaging Reporting and Data System</em> established by the American College of Radiology or if a woman is believed to be at increased risk for breast cancer due to family history or prior personal history of breast cancer, positive genetic testing or other indications as determined by a woman’s physician or advanced practice registered nurse&lt;br&gt;• Updated supporting information to reflect the most current description of services, clinical evidence, and references&lt;br&gt;• Archived previous policy version DIAGNOSTIC 105.18 T2</td>
</tr>
</tbody>
</table>

### INSTRUCTIONS FOR USE

This Clinical Policy provides assistance in interpreting UnitedHealthcare Oxford standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare Oxford reserves the right to modify its Policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice.

The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Oxford Clinical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.